Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EP300 | Q09472 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4296542 | 1.00 | EP300 (0.31) | EP300 | |
| SCHEMBL6642798 | 0.90 | NPSR1 (0.30) | — | |
| SCHEMBL19404 | 0.84 | EP300 (0.31) | EP300 | |
| SCHEMBL19405 | 0.84 | EP300 (0.31) | EP300 | |
| SCHEMBL20278354 | 0.84 | GLO1 (0.39) | — | |
| SCHEMBL14055652 | 0.84 | EP300 (0.31) | EP300 | |
| SCHEMBL1421463 | 0.83 | EP300 (0.37) | EP300 | |
| SCHEMBL6645940 | 0.82 | — | — | |
| SCHEMBL6645938 | 0.82 | — | — | |
| SCHEMBL11650881 | 0.81 | ADRA1A (0.34) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200290974-A1 | FARNESOID X RECEPTOR ANTAGONISTS | HOPE CITY (US) | 2020-09-17 | — | — | US | disclosed |
| US-10611729-B2 | Farnesoid X receptor antagonists | CITY OF HOPE (US) | 2020-04-07 | — | — | US | disclosed |
| WO-2018226150-A1 | PYRAZOLOPYRIMIDINE AS MALT-1 INHIBITORS | MEDIVIR AKTIEBOLAG (SE) | 2018-12-13 | — | — | WO | disclosed |
| US-20180334437-A1 | FARNESOID X RECEPTOR ANTAGONISTS | CITY OF HOPE | 2018-11-22 | — | — | US | disclosed |
| WO-2018141749-A1 | THERAPEUTIC APPLICATIONS OF MALT1 INHIBITORS | MEDIVIR AB (SE) | 2018-08-09 | — | — | WO | disclosed |
| US-9944605-B2 | Farnesoid X receptor antagonists | CITY OF HOPE (US) | 2018-04-17 | — | — | US | disclosed |
| US-20170008851-A1 | FARNESOID X RECEPTOR ANTAGONISTS | CITY OF HOPE | 2017-01-12 | — | — | US | disclosed |
| WO-2015116856-A2 | FARNESOID X RECEPTOR ANTAGONISTS | CITY OF HOPE (US) | 2015-08-06 | — | — | WO | disclosed |
| US-20090286791-A1 | Amide Compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-11-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180334437-A1 | FARNESOID X RECEPTOR ANTAGONISTS | NR1H4, FXR1, FXR2 | EP300 1088/4885 |
| US-20090286791-A1 | Amide Compounds | DLAT, DGAT2, DGAT1 | EP300 63/4885 |
| US-20200290974-A1 | FARNESOID X RECEPTOR ANTAGONISTS | NR1H4, FXR1, FXR2 | EP300 1375/4885 |
| US-10611729-B2 | Farnesoid X receptor antagonists | NR1H4, FXR1, FXR2 | EP300 1088/4885 |
| US-20170008851-A1 | FARNESOID X RECEPTOR ANTAGONISTS | NR1H4, FXR1, FXR2 | EP300 1375/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.